Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).
Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs).
Cellular Dynamics (based in Madison, Wisconsin) is hoping to raise up to $57.3m in its IPO on Nasdaq. The company,...
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
